Extended Data Fig. 12: Combined PI3Kβ inhibition and immunotherapy inhibit tumor growth in mouse models of PTEN-null breast cancer.
From: PI3Kβ controls immune evasion in PTEN-deficient breast tumours
a–b, Tumor-bearing mice were treated with AZD6482 or a monoclonal antibody against mouse PD-1 (αPD-1) alone or in combination, as shown. Tumor growth curves (left panels) and tumor growth inhibition (TGI; right panels) are shown (n = 8 tumors for AZD6482 in (a); n = 10 tumors for other conditions in (a) and (b)). c, Western blot analysis of 4T1 mouse mammary tumor cells with deleted Pten (4T1-sgPten) and parental 4T1 cells. Image is representative of two independent immunoblots. Apparent molecular weights in kDa are indicated. d, Ratio of M2-like polarized (CD206High MHC-II-) to M1-like polarized (CD206- MHC-IIHigh) macrophages (CD11b+ F4/80+) as determined by flow cytometry (n = 10 tumors per group). e, 4T1-sgPten tumor-bearing mice were treated with AZD6482, αPD-1 or the STING agonist MSA2 alone or in combination. Tumor growth curves (left panels) and TGI (right panels) are each shown as two separate plots for clarity, with all plots including the same vehicle and AZD6482 groups for easier comparison (n = 8 tumors for MSA; n = 10 tumors for other conditions). Data for tumor growth curves presented as mean values and s.e.m. Box plots represent median and inter-quartile range, and min-to-max error bars (whiskers). For comparison of multiple mean values (a–b and d–e), one-way ANOVA followed by Tukey’s multiple comparisons tests. Statistical analysis on (e) was performed including all groups in the comparisons, with results shown in two different graphs for easier visual assessment. Flow cytometry gating profiles are available on Supplementary Fig. 9.
